Report updated May 26, 2026
Vivy: GLP1 & GLP 1 Tracker
For individuals prescribed GLP-1 medications like Zepbound, Wegovy, or Ozempic seeking structured health tracking and clinical-led guidance.
Vivy: GLP1 & GLP 1 Tracker is a well-regarded health & fitness app that is available. With a 4.8/5 rating from 653 reviews, it maintains solid user satisfaction.
What is Vivy: GLP1 & GLP 1 Tracker?
Vivy is a doctor-developed health tracking app for GLP-1 medication users on iOS.
Users hire Vivy to manage medication side effects and weight loss progress within a clinically-vetted community, reducing the confusion of self-managed treatment.
Current Momentum
v3.4 · 2mo ago
Maintenance- Maintains consistent clinical-led update cadence.
- Ships community-focused feature iterations.
Active Nemesis
Shotsy GLP-1 Tracker
By Shotsy
Other Rivals
7-Day Rank Pulse 🇺🇸
Health & FitnessNo ranking data
Rating Pulse 🇺🇸
Recent User Mood
What makes this app unique?
What Are The Key Features?
Dedicated forum for users on GLP-1 medications to share experiences and ask questions
Nutrient tracking via image capture of meals to monitor protein intake
Personalized guidance and check-ins designed by a board-certified obesity medicine doctor
How much does it cost?
- Yearly
- Monthly
Subscription-only model for core features, requiring payment via Apple account with auto-renewal.
Who Built It?
Enrichment in progress
Publisher profile available very soon
What other apps does Vita Intelligence make?
What do users think recently?
Medium confidence · 48 reviews analyzed
How did the latest release land?
What is the recent mood?
Recent user voice shows a excited sentiment.
Limited review volume (48 reviews). Sentiment analysis will deepen as more data lands.
View the full user-sentiment analysis
Mood gauge, ratings & review-volume history, every praise / complaint / request, and sentiment over time.
What is the competitive landscape for Vivy: GLP1 & GLP 1 Tracker?
Where is it available?
Localized markets (2)
How's The Health & Fitness Market?
How does it evolve in the Health & Fitness market?
Vivy maintains a 4.77 rating across 653 ratings, establishing a high-trust niche position. The subscription-only model limits mass-market adoption compared to utility-first competitors.
Rank progression
1 active ranking tracked — 30-day window
Which niche is Vivy: GLP1 & GLP 1 Tracker in?
to track medication and health progress
Explore the full Diabetes Management Trackers niche
Every app in this space — 46 tracked, the niche's live rankings, and Marlvel's editorial take on the job-to-be-done.
The rivals identified
Nemeses(1)
Shotsy is the direct market leader for GLP-1 users, offering specialized medication tracking that mirrors Vivy’s core value proposition.
Differentiators
- Advanced medication level estimation provides users with predictive insights into their current drug concentration levels.
- High-frequency release cadence ensures rapid feature iteration and responsiveness to user feedback and platform updates.
- Massive review volume creates a significant social proof barrier that is difficult for new entrants to overcome.
Head to head
Vivy must pivot toward clinical authority and unique educational content to differentiate from Shotsy’s pure-utility dominance.
Contenders(4)
This app overlaps with Vivy by addressing the dietary and lifestyle management required for patients on metabolic medications.
WellView competes for the user's attention regarding medication access, costs, and pharmacy logistics.
It targets the secondary health metrics that GLP-1 users must monitor, creating overlap in the daily logging workflow.
This app competes by controlling the physical fulfillment and prescription management layer of the GLP-1 user journey.
Same space(3)
This app serves the same user base by focusing on the logistical fulfillment of prescriptions and medication reminders.
Unilife competes by offering a broader suite of pharmacy-related services and medication management tools.
Stelo provides hardware-backed health insights that serve as a premium alternative to Vivy's manual tracking.
Differentiators
- Direct integration with continuous glucose biosensors offers objective, real-time metabolic data rather than manual logs.
- Backed by Dexcom’s established brand and infrastructure, providing a high-trust environment for health-conscious users.
Compare Vivy: GLP1 & GLP 1 Tracker against every rival
All rivals in one side-by-side table — identity, store metrics, ratings & sentiment, and strategic intel — plus a head-to-head page for each.
The outtake for Vivy: GLP1 & GLP 1 Tracker
Strengths to defend, gaps to attack
Core Strengths
- Doctor-developed positioning builds clinical trust
- GLP-1 specific community fosters peer-to-peer retention
Critical Frictions
- Subscription-only model for core features limits top-of-funnel conversion
- Lack of automated device integration increases manual logging friction
Growth Levers
- Integration with wearable biosensors for objective metabolic data
- B2B partnerships with clinics for patient management
Market Threats
- Shotsy’s predictive medication visualization tools
- Apple Health integration dominance by established medical apps
What are the next best moves?
Ship free-tier basic tracking because subscription-only core features limit top-of-funnel conversion → increase install velocity
Subscription-only model for core features is the primary barrier to entry.
Trade-off: Pause the coaching-system expansion — top-of-funnel growth is the current priority.
Integrate Apple Health data sync because lack of automated device integration increases manual logging friction → improve retention
Competitors like Blood Sugar Diary offer automated entry, making manual logging a competitive disadvantage.
Trade-off: Deprioritize the community forum UI refresh — data utility is a higher churn risk.
A counter-intuitive read
The clinical-authority moat is a liability if it prevents the app from adopting the frictionless, automated data-sync standards that users now expect from health-tracking utilities.
Feature Gaps vs Competitors
- Automated device connectivity (available in Blood Sugar Diary but missing here)
- Predictive medication level estimation (available in Shotsy but missing here)
Key Takeaways
Vivy holds a strong clinical niche through doctor-led positioning, but the subscription-only barrier leaves it exposed to utility-first rivals, so the team must prioritize free-tier tracking to drive user acquisition.
Where Is It Heading?
Stable
The GLP-1 tracking market is consolidating around utility-first apps that offer automated data synchronization. Vivy must transition from a manual-entry tool to a clinical data hub to remain relevant, or risk losing its user base to competitors with superior device integration.
High rating consistency indicates the clinical-led value proposition resonates with the core user base, stabilizing retention.
Subscription-only access to core features creates a conversion bottleneck that limits growth against free-to-use utility competitors.